Activity of d,l-α-tocopherol (vitamin E) against cardiotoxicity induced by doxorubicin and doxorubicin with cyclophosphamide in mice

Basic and Clinical Pharmacology and Toxicology

Volumn 97, Issue 5, 2005, Pages 311-319

  Bjelogrlic, Snezana K ^a   Radic, Jelena ^b   Jovic, Viktor ^b   Radulovic, Sinisa ^a  

^a National Cancer Research Institute   (Yugoslavia)

^b INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYBUTYRATE DEHYDROGENASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOLUS INJECTION; CARDIOTOXICITY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; HEART MUSCLE INJURY; HEART PROTECTION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENZYMES; FEMALE; HEART DISEASES; MICE; MICE, INBRED BALB C; MYOCARDIUM; VITAMIN E;

ANIMALIA;

EID: 27744491740     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2005.pto_166.x     Document Type: Article

References (58)

1. Albini, A., F. D'Agostini, D. Giunciuglio, I. Paglieri, R. Balansky & S. De Flora: Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine. Int. J. Cancer 1995, 61, 121-129.
2. Armutcu, F., O. Coskun, A. Gurel, S. Sahin, M. Kanter, A. Cihan, K. V. Numanoglu & C. Altinyazar: Vitamin E protects against acetone-induced oxidative stress in rat red blood cells. Cell Biol. Toxicol. 2005, 21, 53-60.
3. Bertelli, R., F. Ginevri, R. Gusmano & G. M. Ghiggeri: Cytotoxic effect of adriamycin and agarose-coupled adriamycin on glomerular epithelial cells: role of free radicals. In Vitro Cell Dev. Biol. 1991, 27A, 799-804.
4. Billingham, M. E., J. W. Mason, M. R. Bristow & J. R. Daniels: Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep. 1978, 62, 865-872.
5. Braverman, A. C., J. H. Antin, M. T. Plappert, E. F. Cook & R. T. Lee: Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J. Clin. Oncol. 1991, 9, 1215-1223.
6. Breed, J. G., A. N. Zimmerman, J. A. Dormans & H. M. Pinedo: Failure of the antioxidant vitamin E to protect against adriamycin-induced cardiotoxicity in the rabbit. Cancer Res. 1980, 40, 2033-2038.
7. Brockes, C., C. Buchli, R. Locher, J. Koch & W. Vetter: Vitamin E prevents extensive lipid peroxidation in patients with hypertension. Brit. J. Biomed. Sci. 2003, 60, 5-8.
8. Chen, A., L. F. Sheu, Y. S. Ho, Y. F. Lin, W. Y. Chou, T. C. Chou & W. H. Lee: Experimental focal segmental glomerulosclerosis in mice. Nephron 1998, 78, 440-452.
9. Dow, E., H. Schulman & E. Agura: Cyclophosphamide cardiac injury mimicking acute myocardial infarction. Bone Marrow Transplant. 1993, 12, 169-172.
10. Ferrans V., J. Sanchez & E. Herman: The role of myocardial biopsy in the diagnosis of anthracycline cardiotoxicity. In: Cancer treatment and the heart. Eds.: F. Muggia, M. Green & J. Speyer. John Hopkins University, Baltimore, MD, 1992, pp. 198-216.
11. Fukuda, F., M. Kitada, T. Horie & S. Awazu: Evaluation of adriamycin-induced lipid peroxidation. Biochem. Pharmacol. 1992, 44, 755-760.
12. Gabizon, A., A. Meshorer & Y. Barenholz: Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J. Natl. Cancer Inst. 1986, 77, 459-469.
13. Gille, L. & H. Nohl: Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic. Biol. Med. 1997, 23, 775-782.
14. Goldberg, M. A., J. H. Antin, E. C. Guinan & J. M. Rappeport: Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986, 68, 1114-1118.
15. Guan, Z., C. Y. Lui, E. Morkin & J. J. Bahl: Oxidative stress and apoptosis in cardiomyocyte induced by high-dose alcohol. J. Cardiovasc. Pharmacol. 2004, 44, 696-702.
16. Herman, E. H., A. el Hage & V. J. Ferrans: Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Toxicol. Appl. Pharmacol. 1988, 92, 42-53.
17. Herman, E. H., A. N. el Hage, V. J. Ferrans & B. Ardalan: Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicol. Appl. Pharmacol. 1985, 78, 202-214.
18. Herman, E. H. & V. J. Ferrans: Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Lab. Invest. 1983, 49, 69-77.
19. Herman, E. H., J. Zhang, D. P. Chadwick & V J. Ferrans: Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer Chemother. Pharmacol. 2000, 45, 329-334.
20. Jaakkola, K., P. Lahteenmaki, J. Laakso, E. Harju, H. Tykka & K. Mahlberg: Treatment with antioxidant and other nutrients in combination with chemotherapy and irradiation in patients with small-cell lung cancer. Anticancer Res. 1992, 12, 599-606.
21. Kang, S. K., C. Y. Ha, K. H. Cho, S. K. Park & U. H. Kim: Changes of lactate dehydrogenase and its isoenzyme activity in renal diseases. Nephron 1991, 57, 55-59.
22. Keizer, H. G., H. M. Pinedo, G. J. Schuurhuis & H. Joenje: Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol. Therap. 1990, 47, 219-231.
23. Kim, C., S. W. Nam, D. Y. Choi, J. H. Choi, E. S. Park, W. K. Jhoo & H. C. Kim: A new antithrombotic agent, aspalatone, attenuated cardiotoxicity induced by doxorubicin in the mouse; possible involvement of antioxidant mechanism. Life Sci. 1997, 60, L75-L82.
24. Krischer, J. P., S. Epstein, D. D. Cuthbertson, A. M. Goorin, M. L. Epstein & S. E. Lipshultz: Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J. Clin. Oncol. 1997, 15, 1544-1552.
25. Krivit, W.: Adriamycin cardiotoxicity amelioration by alpha-tocopherol. Am. J. Pediatr. Hematol. Oncol. 1979, 1, 151-153.
26. Kupari, M., L. Volin, A. Suokas, T. Timonen, P. Hekali & T. Ruutu: Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant. 1990, 5, 91-98.
27. Kurbacher, C. M., U. Wagner, B. Kolster, P. E. Andreotti, D. Krebs & H. W. Bruckner: Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett. 1996, 103, 183-189.
28. Labriola, D. & R. Livingston: Possible interactions between dietary antioxidants and chemotherapy. Oncology (Huntingt) 1999, 13, 1003-1008.
29. Lefrak, E. A., J. Pitha, S. Rosenheim & J. A. Gottlieb: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32, 302-314.
30. Legha, S. S., R. S. Benjamin, B. Mackay, M. Ewer, S. Wallace, M. Valdivieso, S. L. Rasmussen, G. R. Blumenschein & E. J. Freireich: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med. 1982a, 96, 133-139.
31. Legha, S. S., Y. M. Wang, B. Mackay, M. Ewer, G. N. Hortobagyi, R. S. Benjamin & M. K. Ali: Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity. Ann. N. Y. Acad Sci. 1982b, 393, 411-418.
32. Lipshultz, S. E., S. D. Colan, R. D. Gelber, A. R. Perez-Atayde, S. E. Sallan & S. P. Sanders: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. New Engl. J. Med. 1991, 324, 808-815.
33. Mizushima, Y., K. Sassa, T. Hamazaki, T. Fujishita, R. Oosaki & M. Kobayashi: Diuretic response to cyclophosphamide in rats bearing a matrix metalloproteinase-9-producing tumour. Brit. J. Cancer 1998, 78, 1030-1034.
34. Morandi, P., P. A. Ruffini, G. M. Benvenuto, L. La Vecchia, G. Mezzena & R. Raimondi: Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m(2)) cyclophosphamide. Bone Marrow Transplant. 2001, 28, 277-282.
35. Myers, C. E., W. McGuire & R. Young: Adriamycin: amelioration of toxicity by alpha-tocopherol. Cancer Treat. Rep. 1976, 60, 961-962.
36. Nwankwoala, R. N. & W. L. West: Inhibition of alpha-tocopherol and calcium calmodulin-stimulated phosphodiesterase activity in vitro by anthracyclines. Clin. Exp. Pharmacol. Physiol. 1988, 15, 805-814.
37. Pihkala, J., U. M. Saarinen, U. Lundstrom, M. Salmo, K. Virkola, K. Virtanen, M. A. Siimes & E. Pesonen: Effects of bone marrow transplantation on myocardial function in children. Bone Marrow Transplant. 1994, 13, 149-155.
38. Praga, C., G. Beretta, P. L. Vigo, G. R. Lenaz, C. Pollini, G. Bonadonna, R. Canetta, R. Castellani, E. Villa, C. G. Gallagher, H. von Melchner, M. Hayat, P. Ribaud, G. De Wasch, W. Mattsson, R. Heinz, R. Waldner, K. Kolaric, R. Buehner, W. Bokkel-Huyninck, N. I. Perevodchikova, L. A. Manziuk, H. J. Senn & A. C. Mayr: Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat. Rep. 1979, 63, 827-834.
39. Prasad, K. N., J. Edwards-Prasad, S. Ramanujam & A. Sakamoto: Vitamin E increases the growth inhibitory and differentiating effects of tumor therapeutic agents on neuroblastoma and glioma cells in culture. Proc. Soc. Exp. Biol. Med. 1980, 164, 158-163.
40. Rezk, B. M., G. R. Haenen, W. J. Van Der Vijgh & A. Bast: The extraordinary antioxidant activity of vitamin E phosphate. Biochim. Biophys. Acta 2004, 1683, 16-21.
41. Sacks, P. G., D. Harris & T. C. Chou: Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents. Int. J. Cancer 1995, 61, 409-415.
42. Sallan, S. E. & L. A. Clavell: Cardiac effects of anthracyclines used in the treatment of childhood acute lymphoblastic leukemia: a 10-year experience. Semin. Oncol. 1984, 11, 19-21.
43. Schnell, J. W., R. A. Anderson, J. E. Stegner, S. P. Schindler & R. B. Weinberg: Effects of a high polyunsaturated fat diet and vitamin E supplementation on high-density lipoprotein oxidation in humans. Atherosclerosis 2001, 159, 459-466.
44. Speyer, J. L., M. D. Green, A. Zeleniuch-Jacquotte, J. C. Wernz, M. Rey, J. Sanger, E. Kramer, V. Ferrans, H. Hochster & M. Meyers: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol. 1992, 10, 117-127.
45. Swain, S. M., F. S. Whaley, M. C. Gerber, M. S. Ewer, J. R. Bianchine & R. A. Gams: Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J. Clin. Oncol. 1997a, 15, 1333-1340.
46. Swain, S. M., F. S. Whaley, M. C. Gerber, S. Weisberg, M. York, D. Spicer, S. E. Jones, S. Wadler, A. Desai, C. Vogel, J. Speyer, A. Mittelman, S. Reddy, K. Pendergrass, E. Velez-Garcia, M. S. Ewer, J. R. Bianchine & R. A. Gams: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol. 1997b, 15, 1318-1332.
47. Taper, H. S., J. de Gerlache, M. Lans & M. Roberfroid: Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pre-treatment. Int. J. Cancer 1987, 40, 575-579.
48. Tian, N., K. D. Thrasher, P. D. Gundy, M. D. Hughson & R. D. Manning, Jr.: Antioxidant treatment prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. Hypertension 2005, 45, 934-939.
49. van Haaften, R. I., G. R. Haenen, C. T. Evelo & A. Bast: Effect of vitamin E on glutathione-dependent enzymes. Drug Metab. Rev. 2003, 35, 215-253.
50. Van Vleet, J. F. & V. J. Ferrans: Evaluation of vitamin E and selenium protection against chronic adriamycin toxicity in rabbits. Cancer Treat. Rep. 1980, 64, 315-317.
51. Van Vleet, J. F., V. J. Ferrans & W. E. Weirich: Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Amer. J. Pathol. 1980, 99, 13-42.
52. Vinitha, R., M. Thangaraju & P. Sachdanandam: Effect of administering cyclophosphamide and vitamin E on the levels of tumor-marker enzymes in rats with experimentally induced fibrosarcoma. Jap. J. Med. Sci. Biol. 1995, 48, 145-156.
53. Von Hoff, D. D., M. W. Layard, P. Basa, H. L. Davis, Jr., A. L. Von Hoff, M. Rozencweig & F. M. Muggia: Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 1979, 91, 710-717.
54. Wagdi, P., M. Fluri, B. Aeschbacher, A. Fikrle & B. Meier: Cardioprotection in patients undergoing chemo- and/or radiotherapy for neoplastic disease. A pilot study. Jap. Heart J. 1996, 37, 353-359.
55. Wahab, M. H., E. S. Akoul & A. A. Abdel-Aziz: Modulatory effects of melatonin and vitamin E on doxorubicin-induced cardiotoxicity in Ehrlich ascites carcinoma-bearing mice. Tumori 2000, 86, 157-162.
56. Weijl, N. I., F. J. Cleton & S. Osanto: Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat. Rev. 1997, 23, 209-240.
57. Working, P. K., M. S. Newman, T. Sullivan & J. Yarrington: Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. J. Pharmacol. Exp. Therap. 1999, 289, 1128-1133.
58. Zaidi, S. M., T. M. Al Qirim & N. Banu: Effects of antioxidant vitamins on glutathione depletion and lipid peroxidation induced by restraint stress in the rat liver. Drugs R. D. 2005, 6, 157-165.